Genomics

A growing body of evidence suggests that the reason one individual responds differently from another to the same drug and why some patients are more likely to respond to a particular treatment than others, may be found in the genetic variations between individuals.  Once identified, these genetic variations can serve as genetic markers playing a crucial role in the development of drugs of the future, tailored to an individual's specific needs.

UCB has made a strategic investment in genomic analysis technology including Affymetrix microarrays and TaqMan® Real-Time Quantative PCR. A large dataset handling capability has also been established using technology from Genedata. The ultimate goal of this initiative is to exploit genomics at all stages of drug discovery and development. UCB hopes to determine the feasibility of patient stratification through gene expression markers and add to the understanding of the mode of action of therapeutic molecules at a molecular level.